Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice
Open accessAbstract
Objective—: To determine the efficacy of long-term anti-miR-33 therapy on the progression of atherosclerosis in high-fat, high-cholesterol–fed Ldlr –/– mice. Methods and Results—: Ldlr –/– mice received saline, or control or anti-miR-33 oligonucleotides once a week for 14 weeks. The treatment was effective, as measured by reduced levels of hepatic miR-33 and increased hepatic expression of miR-33 targets. Analysis of plasma samples revealed an initial elevation in high-density lipoprotein cholesterol after 2 weeks of treatment that was not sustained by the end of the experiment. Additionally, we found a significant increase in circulating triglycerides in anti-miR-33–treated mice, compared with controls. Finally, examination of atheromata revealed no significant changes in the size or composition of lesions between the 3 groups. Conclusion—: Prolonged silencing of miR-33 fails to maintain elevated plasma high-density lipoprotein cholesterol and does not prevent the progression of atherosclerosis in Ldlr –/– mice.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other similar studies did not observe any beneficial effects of anti-miR-33 therapy on atherogenesis.
“However, other similar studies did not observe any beneficial effects of anti-miR-33 therapy on atherogenesis (Marquart et al., 2013).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Marquart et al., 2013
Another study did not find reduced aortic lesions in anti-miR-33 treated mice.
“Another study did not find reduced aortic lesions in anti-miR-33 treated mice (Marquart et al., 2013).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Marquart et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260 · see citing works
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957 · see citing works
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706 · see citing works
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 3× · see citing works
“increase HDL-c and accelerate the regression of atherosclerotic lesions in hyperlipidemic Ldlr mice switched to standard chow diet.(7) However, no reports are yet available”
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling
Dávalos, A., Goedeke, L., Smibert, P., Ramírez, C. M., Warrier, N. P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102281108 · Cited by 670 · see citing works
miR-33 links SREBP-2 induction to repression of sterol transporters
Marquart, T. J., Allen, R. M., Ory, D. S., & Baldán, Á. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005191107 · Cited by 562 · see citing works
Self-citationHorie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384 · see citing works
Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
Gerin, I., Clerbaux, L.-A., Haumont, O., Lanthier, N., Das, A. K., Burant, C. F., Leclercq, I. A., MacDougald, O. A., & Bommer, G. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152090 · Cited by 382 · see citing works
The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?
Rader, D., & Tall, A. (2012) · Nature Medicine · doi:10.1038/nm.2937 · Cited by 293 · see citing works
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE <sup>−/−</sup> Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220 · see citing works
Eck, M. V., Singaraja, R. R., Ye, D., Hildebrand, R. B., James, E. R., Hayden, M. R., & van Berkel, T. J. C. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000208364.22732.16 · Cited by 167 · see citing works
Allen, R. M., Marquart, T. J., Albert, C. J., Suchy, F. J., Wang, D. Q. ‐., Ananthanarayanan, M., Ford, D. A., & Baldán, Á. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201228 · Cited by 159 · see citing works
Self-citationSacco, J., & Adeli, K. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283534c9f · Cited by 96 · see citing works
Joyce, C. W., Wagner, E. M., Basso, F., Amar, M. J., Freeman, L. A., Shamburek, R. D., Knapper, C. L., Syed, J., Wu, J., Vaisman, B. L., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604526200 · Cited by 80 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
MicroRNA Regulation of Atherosclerosis
Feinberg, M. W., & Moore, K. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306300 · Cited by 630 · see citing works
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625 · see citing works
Ouimet, M., Ediriweera, H. N., Gundra, U. M., Sheedy, F. J., Ramkhelawon, B., Hutchison, S. B., Rinehold, K., van Solingen, C., Fullerton, M. D., Cecchini, K., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81676 · Cited by 394 · see citing works
Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP
Xu, X., So, J.-S., Park, J.-G., & Lee, A.-H. (2013) · Seminars in liver disease (Print) · doi:10.1055/s-0033-1358523 · Cited by 299 · see citing works
Kumar, S., Kim, C. W., Simmons, R., & Jo, H. (2014) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303425 · Cited by 265 · see citing works
MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice
Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Nakao, T., Nishiga, M., Usami, S., Izuhara, M., Sowa, N., Yahagi, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3883 · Cited by 230 · see citing works
Non-coding RNAs in cardiovascular cell biology and atherosclerosis
Fasolo, F., Gregoli, K. D., Mäegdefessel, L., & Johnson, J. L. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz203 · Cited by 202 · see citing works
Rotllan, N., Ramírez, C. M., Aryal, B., Esau, C. C., & Fernández-Hernando, C. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301732 · Cited by 174 · see citing works
MicroRNA-144 Regulates Hepatic ABCA1 and Plasma HDL Following Activation of the Nuclear Receptor FXR
Vallim, T. Q. D. A., Tarling, E., Kim, T., Civelek, M., Baldán, Á., Esau, C. C., & Edwards, P. (2013) · Circulation Research · doi:10.1161/circresaha.112.300648 · Cited by 142 · see citing works
Self-citationRecent Highlights of ATVB Atherosclerosis
Lu, H. S., & Daugherty, A. (2015) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305380 · Cited by 76 · see citing works
miRNAs in atherosclerotic plaque initiation, progression, and rupture
Andreou, I., Sun, X., Stone, P. H., Edelman, E. R., & Feinberg, M. W. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.003 · Cited by 153 · see citing works
MicroRNAs in the Pathobiology and Therapy of Atherosclerosis
Laffont, B., & Rayner, K. J. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.01.001 · Cited by 151 · see citing works
Goedeke, L., Salerno, A., Ramírez, C. M., Guo, L., Allen, R. M., Yin, X., Langley, S. R., Esau, C., Wanschel, A., Fisher, E. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404046 · Cited by 145 · see citing works
Madrigal‐Matute, J., Rotllán, N., Aranda, J. F., & Fernandez-Hernando, C. F. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0322-z · Cited by 142 · see citing works
Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis
Price, N. L., Rotllan, N., Canfrán-Duque, A., Zhang, X., Pati, P., Arias, N., Moen, J., Mayr, M., Ford, D. A., Baldán, Á., et al. (2017) · Cell reports · doi:10.1016/j.celrep.2017.10.023 · Cited by 129 · see citing works
Self-citationLiver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?
Willeit, P., Skroblin, P., Kiechl, S., Fernández-Hernando, C., & Mayr, M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw146 · Cited by 124 · see citing works
Rottiers, V., Obad, S., Petri, A., McGarrah, R., Lindholm, M. W., Black, J. C., Sinha, S., Goody, R. J., Lawrence, M. S., deLemos, A. S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006840 · Cited by 121 · see citing works
MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis
Schober, A., Nazari-Jahantigh, M., & Weber, C. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.38 · Cited by 113 · see citing works
microRNAs in lipoprotein metabolism and cardiometabolic disorders
Rotllán, N., Price, N. L., Pati, P., Goedeke, L., & Fernandez-Hernando, C. F. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.025 · Cited by 111 · see citing works
microRNA Therapeutics in Cardiovascular Disease Models
Dangwal, S., & Thum, T. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135957 · Cited by 109 · see citing works
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis
Novák, J., Olejníčková, V., Tkáčová, N., & Santulli, G. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22380-3_5 · Cited by 109 · see citing works
Distel, E., Barrett, T. J., Chung, K., Girgis, N., Parathath, S., Essau, C. C., Murphy, A., Moore, K., & Fisher, E. (2014) · Circulation Research · doi:10.1161/circresaha.115.304164 · Cited by 95 · see citing works
Javadifar, A., Rastgoo, S., Banach, M., Jamialahmadi, T., Johnston, T., & Sahebkar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052529 · Cited by 89 · see citing works
Wu, Z., He, Y., Li, D., Fang, X., Shang, T., Zhang, H., & Zheng, X. (2017) · PubMed Central · Cited by 97 · see citing works
miR-33-5p, a novel mechano-sensitive microRNA promotes osteoblast differentiation by targeting Hmga2
Wang, H., Sun, Z., Wang, Y., Hu, Z.-B., Zhou, H., Zhang, L.-C., Hong, B., Zhang, S., & Cao, X.-S. (2016) · Scientific Reports · doi:10.1038/srep23170 · Cited by 95 · see citing works
Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease
Peters, L. J. F., Biessen, E. A. L., Hohl, M., Weber, C., van der Vorst, E. P. C., & Santovito, D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00793 · Cited by 97 · see citing works
microRNA control of HDL Metabolism and Function
Rayner, K. J., & Moore, K. (2014) · Circulation Research · doi:10.1161/circresaha.114.300645 · Cited by 89 · see citing works
Goedeke, L., Rotllán, N., Ramírez, C. M., Aranda, J. F., Canfrán‐Duque, A., Araldi, E., Fernández‐Hernando, A., Langhi, C., de Cabo, R., Baldán, Á., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.033 · Cited by 70 · see citing works
Self-citationKarunakaran, D., Richards, L., Geoffrion, M., Barrette, D., Gotfrit, R. J., Harper, M., & Rayner, K. J. (2015) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306404 · Cited by 65 · see citing works
MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases
Aranda, J. F., Madrigal‐Matute, J., Rotllán, N., & Fernandez-Hernando, C. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.014 · Cited by 66 · see citing works
Liao, B., Chen, R., Lin, F., Mai, A., Chen, J., Li, H., Xu, Z., & Dong, S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26448 · Cited by 65 · see citing works
Micro-RNAs and High-Density Lipoprotein Metabolism
Canfrán‐Duque, A., Lin, C., Goedeke, L., Suárez, Y., & Fernandez-Hernando, C. F. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307028 · Cited by 64 · see citing works
MicroRNAs in obesity-associated disorders
Abente, E. J., Subramanian, M., Ramachandran, V., & Najafi-Shoushtari, S. H. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.09.018 · Cited by 63 · see citing works
The role of miRNAs in cardiovascular disease risk factors
Buie, J. N. J., Goodwin, A., Cook, J., Halushka, P., & Fan, H.-K. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.067 · Cited by 59 · see citing works
Anti-miR-148a regulates platelet FcγRIIA signaling and decreases thrombosis in vivo in mice.
Zhou, Y.-H., Abraham, S., André, P., Edelstein, L., Shaw, C., Dangelmaier, C., Tsygankov, A., Kunapuli, S., Bray, P., & Mckenzie, S. (2015) · Blood · doi:10.1182/blood-2015-02-631135 · Cited by 54 · see citing works
Canfrán‐Duque, A., Ramírez, C. M., Goedeke, L., Lin, C., & Fernandez-Hernando, C. F. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu140 · Cited by 58 · see citing works
Elucidating the contributory role of microRNA to cardiovascular diseases (a review)
Johnson, J. L. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.10.010 · Cited by 59 · see citing works
Eyeballing Cholesterol Efflux and Macrophage Function in Disease Pathogenesis
Séne, A., & Apte, R. (2013) · Trends in endocrinology and metabolism · doi:10.1016/j.tem.2013.10.007 · Cited by 62 · see citing works
Relevance of microRNA in metabolic diseases
Price, N., Ramírez, C., & Fernández-Hernando, C. (2014) · Critical reviews in clinical laboratory sciences · doi:10.3109/10408363.2014.937522 · Cited by 52 · see citing works
MicroRNAs and metabolic disorders – where are we heading?
Śliwińska, A., Kasińska, M., & Drzewoski, J. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65229 · Cited by 55 · see citing works
Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins
Singh, A. K., Aryal, B. K., Zhang, X., Fan, Y., Price, N. L., Suárez, Y., & Fernandez-Hernando, C. F. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.11.026 · Cited by 54 · see citing works
Non-coding RNAs in Lipid Metabolism
Zhang, X.-B., Price, N., & Fernández-Hernando, C. (2018) · Vascular pharmacology · doi:10.1016/j.vph.2018.06.011 · Cited by 52 · see citing works
Stamatikos, A., Knight, E., Vojtech, L. N., Bi, L., Wacker, B. K., Tang, C., & Dichek, D. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.245 · Cited by 54 · see citing works
Huang, K., Bao, H., Yan, Z.-Q., Wang, L., Zhang, P., Yao, Q.-P., Shi, Q., Chen, X.-H., Wang, K.-X., Shen, B.-R., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvw257 · Cited by 54 · see citing works
Novák, J., Vašků, J. B., Kára, T., & Novák, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/275867 · Cited by 52 · see citing works
HDL and microRNA therapeutics in cardiovascular disease
Michell, D. L., & Vickers, K. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.001 · Cited by 45 · see citing works
Small but smart: MicroRNAs orchestrate atherosclerosis development and progression
Santovito, D., Egea, V., & Weber, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.12.013 · Cited by 44 · see citing works
The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases
Sethupathy, P. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0745-3 · Cited by 44 · see citing works
MicroRNA regulation of cholesterol metabolism
Citrin, K. M., Fernandez-Hernando, C. F., & Suárez, Y. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14566 · Cited by 44 · see citing works
MicroRNAs as therapeutic targets in atherosclerosis
Loyer, X., Mallat, Z., Boulanger, C., & Tedgui, A. (2015) · Expert opinion on therapeutic targets · doi:10.1517/14728222.2014.989835 · Cited by 41 · see citing works
Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33
Allen, R. M., Marquart, T. J., Jesse, J. J., & Baldán, Á. (2014) · Circulation Research · doi:10.1161/circresaha.115.303100 · Cited by 38 · see citing works
Self-citationMicroRNA-33a/b in lipid metabolism – novel “thrifty” models.
Ono, K., Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Yokode, M., Kita, T., & Kimura, T. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1252 · Cited by 30 · see citing works
miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
Price, N. L., Goedeke, L., Suárez, Y., & Fernández‐Hernando, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012606 · Cited by 36 · see citing works
van Eck, M. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000088 · Cited by 25 · see citing works
MicroRNAs and Lipoprotein Metabolism
Horie, T., Baba, O., Kuwabara, Y., Yokode, M., Kita, T., Kimura, T., & Ono, K. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.20859 · Cited by 29 · see citing works
Macrophage miRNAs in atherosclerosis.
Karunakaran, D., & Rayner, K. J. (2016) · Biochimica et Biophysica Acta · doi:10.1016/j.bbalip.2016.02.006 · Cited by 30 · see citing works
Coenzyme Q10 Increases Cholesterol Efflux and Inhibits Atherosclerosis Through MicroRNAs
Allen, R. M., & Vickers, K. C. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303741 · Cited by 29 · see citing works
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24 · see citing works
A big role for small RNAs in HDL homeostasis
Ouimet, M. I., & Moore, K. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036327 · Cited by 21 · see citing works
MOVAS Cells: A Versatile Cell Line for Studying Vascular Smooth Muscle Cell Cholesterol Metabolism
Esobi, I. C., Barksdale, C., Heard‐Tate, C., Powell, R. R., Bruce, T. F., & Stamatikos, A. (2021) · Lipids · doi:10.1002/lipd.12303 · Cited by 21 · see citing works
MicroRNAs and Cardiovascular Disease
Fernández-Hernando, C., & Baldán, Á. (2013) · Current Genetic Medicine Reports · doi:10.1007/s40142-013-0008-4 · Cited by 29 · see citing works
Self-citationCuadrado, I., Saura, M., Castejón, B., Martin, A. M., Herruzo, I., Balatsos, N. A. A., Zamorano, J. L., & Zaragoza, C. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.5 · Cited by 19 · see citing works
Mallat, Z. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309730 · Cited by 19 · see citing works
MicroRNA-Management of Lipoprotein Homeostasis
Sun, X., & Feinberg, M. W. (2014) · Circulation Research · doi:10.1161/circresaha.114.304228 · Cited by 19 · see citing works
Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease
Calway, T., & Kim, G. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414552902 · Cited by 17 · see citing works
Kowara, M., Borodzicz-Jażdżyk, S., Rybak, K., Kubik, M., & Cudnoch-Jędrzejewska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115718 · Cited by 17 · see citing works
miRNAs and High-Density Lipoprotein metabolism
Baldán, Á., & Vallim, T. Q. D. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.021 · Cited by 17 · see citing works
Self-citationDevelopment of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 17 · see citing works
Anti-atherosclerosis or No Anti-atherosclerosis That is the miR-33 question
Näär, A. (2013) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.301021 · Cited by 18 · see citing works
Esobi, I., Oladosu, O., Echesabal-Chen, J., Powell, R., Bruce, T., & Stamatikos, A. (2023) · Journal of Lipids · doi:10.1155/2023/8241899 · Cited by 16 · see citing works
Zhang, Y., Ma, X., Li, X., Zhang, T., Qin, M., & Ren, L. (2018) · BioMed Research International · doi:10.1155/2018/9424186 · Cited by 16 · see citing works
Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis
Miyagawa, S., Horie, T., Nishino, T., Koyama, S., Watanabe, T., Baba, O., Yamasaki, T., Sowa, N., Otani, C., Matsushita, K., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301902 · Cited by 14 · see citing works
Liver-specific microRNA-185 knockout promotes cholesterol dysregulation in mice
Chen, C., Matye, D. J., Wang, Y., & Li, T.-G. (2020) · Liver Research · doi:10.1016/j.livres.2020.09.001 · Cited by 10 · see citing works
Vladimirov, S. S., Tomasevic, M., Popov, N., Munjas, J., de Gonzalo‐Calvo, D., & Sopić, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.005 · Cited by 13 · see citing works
Evolving targets for lipid‐modifying therapy
Do, R. Q., Nicholls, S. J., & Schwartz, G. G. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404000 · Cited by 13 · see citing works
Baba, O., Horie, T., Nakao, T., Hakuno, D., Nakashima, Y., Nishi, H., Kuwabara, Y., Nishiga, M., Nishino, T., Ide, Y., et al. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00604-17 · Cited by 12 · see citing works
Kaur, K. K. (2015) · Journal of Health & Medical Informatics · doi:10.4172/2157-7420.1000184 · Cited by 10 · see citing works
Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions
Guo, Y., Luo, F., Yi, Y., & Xu, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0381-6 · Cited by 10 · see citing works
Very low HDL levels: clinical assessment and management
Bonilha, I., Luchiari, B., Nadruz, W., & Sposito, A. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000585 · Cited by 12 · see citing works
Antisense Oligonucleotides, microRNAs, and Antibodies
Dávalos, A., & Chroni, A. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_22 · Cited by 10 · see citing works
Truths and Controversies Concerning the Role of miRNAs in Atherosclerosis and Lipid Metabolism
Baldán, Á., & Fernández-Hernando, C. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000358 · Cited by 10 · see citing works
Self-citationShi, X., Pan, S., Li, L., Li, Y., Ma, W., Wang, H., Xu, C., Li, L., & Wang, D. (2020) · Aging · doi:10.18632/aging.103079 · Cited by 7 · see citing works
Oladosu, O., Chin, E., Barksdale, C., Powell, R. R., Bruce, T., & Stamatikos, A. (2024) · Pathophysiology · doi:10.3390/pathophysiology31010009 · Cited by 7 · see citing works
Quest for new biomarkers in atherosclerosis.
Cho, Y., & Baldán, Á. (2013) · Europe PMC (PubMed Central) · Cited by 8 · see citing works
Self-citationHemostatic disorders of the menopausal period: the role of microRNA
Stachowiak, G., Zając, A. E., Nowak, M., Stetkiewicz, T., & Wilczyński, J. (2015) · Przeglad menopauzalny = Menopause review · doi:10.5114/pm.2015.52155 · Cited by 7 · see citing works
Cochain, C., & Zernecke, A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000108 · Cited by 9 · see citing works
Epigenetic factors in atherogenesis: microRNA
Smirnova, A. V., Sukhorukov, V. N., Карагодин, В. П., & Orekhov, A. N. (2016) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20166202134 · Cited by 7 · see citing works
Huang, K., Pokhrel, A., Echesabal-Chen, J., Scott, J., Bruce, T., Jo, H., & Stamatikos, A. (2025) · Medicina · doi:10.3390/medicina61020329 · Cited by 4 · see citing works
Scherrer, D. Z., Zago, V. H. D. S., Parra, E. S., Avansini, S. H., Panzoldo, N. B., Alexandre, F., Baracat, J., Nakandakare, E. R., Quintão, E. C. R., & de Faria, E. C. (2015) · Gene · doi:10.1016/j.gene.2015.05.074 · Cited by 4 · see citing works
Noncoding RNAs in Platelet Biology
Edelstein, L. C., & Bray, P. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_18 · Cited by 3 · see citing works
Ekici, S., & Özmen, Ö. (2020) · Journal of Equine Veterinary Science · doi:10.1016/j.jevs.2020.103218 · Cited by 2 · see citing works
Montaño-Samaniego, M., Sánchez-Cedillo, J., Lucas-González, A., Bravo-Estupiñan, D. M., Alarcón-Hernández, E., Rivera-Gutiérrez, S., Balderas-López, J. A., & Ibáñez-Hernández, M. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090445 · Cited by 2 · see citing works
Nesan, D., & Ng, D. S. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.937523 · Cited by 2 · see citing works
MicroRNA Regulation of HDL Homeostasis
Sun, X., & Feinberg, M. W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00010-0 · Cited by 2 · see citing works
Noncoding RNAs in Cholesterol Metabolism and Atherosclerosis
Price, N., & Fernández-Hernando, C. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-52945-5_2 · Cited by 1 · see citing works
MicroRNAs and Cardiovascular Diseases
Henderson, J. M., Farina, F. M., & Santovito, D. (2024) · Epigenetics and human health · doi:10.1007/978-3-031-64788-8_9 · Cited by 1 · see citing works
MicroRNAs in the Pathogenesis, Diagnosis, and Treatment of Liver Disease
Madison, B., & Kerr, T. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800553-8.00004-4 · Cited by 1 · see citing works
Therapies Targeting HDLc Levels and HDL Function
Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 1 · see citing works
In vitro veritas: 90 years of biochemistry at Saint Louis University.
Eissenberg, J. C., & Di Cera, E. (2013) · Europe PMC (PubMed Central)
Role of microRNA-21 in atherogenesis.
Hamed-Berair, R. E. (2016) · doi:10.18297/etd/2431
- Authors
- Marquart, T. J., Wu, J., Lusis, A. J., & Baldán, Á.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2013-03
- Volume
- 33
- Issue
- 3
- Pages
- 455-458
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC3587119
- OpenAlex
- W2169384530
- Cited by
- 110
- References
- 14
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 14 · 2016: 18 · 2015: 15 · 2014: 18 · 2013: 16
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Saint Louis University
- National Heart, Lung, and Blood Institute (HL030568, HL095154, P01HL030568, R01HL095154, HL107794, R01HL107794)
- Topics
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- miR-33, atherosclerosis progression, LDL receptor-deficient mice, HDL cholesterol, high-fat high-cholesterol diet, microRNA silencing
- MeSH terms
- Animals, Aorta, Aortic Diseases, Cholesterol, Dietary, Disease Models, Animal, Cholesterol, HDL, Liver, Male, Receptors, LDL, Time Factors, Triglycerides, Biomarkers, Down-Regulation, Oligonucleotides, Antisense, Mice, Knockout, Disease Progression, MicroRNAs, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
